	Phase	Lymphodeplection	IL2 dosage	Tumor Antigen	Restriction	Cell product	TCR production	Cell delivery
Chodon T et al. 2014 [12]	Ш	CF 60 + FLU 25	HD	MART1	HLA A*0201	Peripheral T cells	Retroviral transduction	intravenous
Dréno B et al. 2021 [13]	1/11	None	LDa	MART1/MELOE	HLA A*0201	Peripheral T cells	Cocultured with Ag and FACS sorted	intravenous
Duval L et al. 2015 [18]	I	None	None	MART1	HLA A*0201	T cell line Ccure 709	Retroviral transduction	intratumoral
Fontana R et al. 2009 [19]	I	None	None	MAGE-A3	HLA A*0201	Peripheral T cells	Retroviral transduction	intravenous
Johnson LA et al. 2009/1		CF 60 + FLU 25	HD	Cohort 1: MART1		Dorinhoral T colls	Detroviral transduction	intravenous
[20]	11			Cohort 2: gp100		Peripheral T cells	Recoviral transduction	
Khammari A et al. 2009 [21]	П	None	LD₀	MART1	HLA A*0201	Peripheral T cells	Cocultured with Ag	intravenous
Lu YC et al. 2017 [22]	lb	CF 60 + FLU 25	HD	MAGE-A3	HLA DP-B1*0401	Peripheral T cells/CD4+ fraction	Retroviral transduction	intravenous
Mackensen A et al. 2006 [23]	I	None	LDc	MART1	HLA A*0201	Peripheral T cells/CD8+ fraction	Cocultured with Ag-pulsed DC	intravenous
Mitchell MS et al. 2002 [24]	Ι	None	None	Tyrosinase	HLA A*0201	Peripheral T cells/CD8+ fraction	Cocultured with mononuclear as APCs	intravenous
Morgan RA et al. 2006 [25]	Ι	CF 60 + FLU 25	HD	MART1	HLA A*0201	Peripheral T cells/CD8+ fraction	Retroviral transduction	intravenous
Morgan 2013 RA et al. 2013 [14]	Ш	CF 60 + FLU 25	HD	MAGE-A3	HLA A*0201	Peripheral T cells/CD8+ fraction	Retroviral transduction	intravenous
Robbins PF et al. 2011 [16]	Ι	CF 60 + FLU 25	HD	NYESO	HLA A*0201	Peripheral T cells/CD3+ fraction	Retroviral transduction	intravenous
Robbins PF et al. 2015 [15]	Ш	CF 60 + FLU 25	HD	NYESO	HLA A*0201	Peripheral T cells/CD3+ fraction	Retroviral transduction	intravenous
Voc C at al. 2002/1 [17]	I	None	LDd	Cohort 1: MART1		Peripheral T cells/CD8+	Cocultured with immunogenic	intravenous
ree c et al. 2002/1 [1/]				Cohort 2: gp100		fraction	epitopes	

Lymphodeplection: CF 60 + FLU 25 [Cyclophosphamide 60 mg/kg for 2 days followed bu Fludarabine 25 mg/m2 for 5 days]; IL2 dosage: HD [720.000 IU/KG q8h to tolerance]; LD [any IL2 dose below that for HD]: a) IL2 s.c. delivered at 6MU from D1-5; b) IL2 s.c. delivered 9MUx3 D1-5 and D8-12 together with s.c. IFN at 9MUx3 during 4 weeks ; c) IL2 s.c. delivered 3MU for 6 days; d) IL2 s.c. delivered at increasing dosage 0,25/0,5/1MU/m2 q12h for 14 days ; Ag: Antigen; DC: Dendritic Cell; APC: Antigen Presenting Cell



Egger's test p = 0,12

Α	Effect Size	Weight	В		Effect Size	Weight
Study	with 95% CI	(%)	Study		with 95% CI	(%)
No			No			
Duval L et al. 2015	0.20 [0.10, 0.30]	7.65	Duval L et al. 2015		0.20 [0.10, 0.30]	6.91
Fontana R et al. 2009	0.11 [0.01, 0.21]	7.65	Fontana R et al. 2009		0.22 [0.08, 0.36]	6.60
Khammari A et al. 2009 —	0.42 [0.29, 0.55]	7.15	Khammari A et al. 2009		0.50 [0.37, 0.63]	6.68
Mitchell MS et al. 2002 -	0.10 [0.01, 0.19]	7.80	Mitchell MS et al. 2002		0.10 [0.01, 0.19]	6.98
Heterogeneity: $\tau^2 = 0.02$, $I^2 = 86.91\%$, $H^2 = 7.64$	0.20 [0.06, 0.34]		Heterogeneity: $\tau^2 = 0.03$, $I^2 = 89.15\%$, $H^2 = 9.22$		0.25 [0.08, 0.42]	
Test of $\theta = \theta_j$: Q(3) = 18.91, p = 0.00			Test of $\theta_i = \theta_j$: Q(3) = 25.83, p = 0.00			
LD			LD			
Dréno B et al. 2021	0.16 [0.01, 0.31]	6.78	Dréno B et al. 2021		0.16 [0.01, 0.31]	6.51
Mackensen A et al. 2006	- 0.27 [0.14, 0.40]	7.15	Mackensen A et al. 2006		0.36 [0.22, 0.50]	6.60
Yee C et al. 2002/1	0.40 [0.18, 0.62]	5.49	Yee C et al. 2002/1		- 0.80 [0.62. 0.98]	6.22
Yee C et al. 2002/2	- 0.20 [0.01, 0.39]	6.04	Yee C et al. 2002/2		— 0.80 [0.62, 0.98]	6.22
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 4.36\%$, $H^2 = 1.05$	0.24 [0.16, 0.32]		Heterogeneity: $T^2 = 0.10 I^2 = 93.75\% H^2 = 16.01$		0.53[0.21_0.84]	
Test of $\theta = \theta_j$: Q(3) = 3.64, p = 0.30			Test of $\theta_i = \theta_j$: Q(3) = 46.42, p = 0.00			
HD						
Johnson LA et al. 2009/1	- 0.30 [0.20, 0.40]	7.65	Chadan T at al. 2014		0.54[0.40, 0.69]	6 60
Johnson LA et al. 2009/2	0.19 [0.10, 0.28]	7.80			0.34 [0.40, 0.08]	6.01
Morgan RA et al. 2006	0.12 [0.04, 0.20]	7.94			0.30 [0.20, 0.40]	0.91
Morgan 2013 RA et al. 2013	0.56 [0.40, 0.72]	6.60	Johnson LA et al. 2009/2		0.19[0.10, 0.28]	0.98
Robbins PF et al. 2011	0.55 [0.44, 0.66]	7.49	Morgan RA et al. 2006		0.12[0.04, 0.20]	7.04
Robbins PF et al. 2015 —	0.45 [0.30, 0.60]	6.78	Morgan 2013 RA et al. 2013		0.56 [0.40, 0.72]	6.41
Heterogeneity: $\tau^2 = 0.03$, $I^2 = 91.77\%$, $H^2 = 12.15$	0.35 [0.20, 0.51]		Robbins PF et al. 2011		0.55 [0.44, 0.66]	6.84
Test of $\theta_i = \theta_j$: Q(5) = 61.32, p = 0.00			Robbins PF et al. 2015		0.45 [0.30, 0.60]	6.51
			Heterogeneity: $\tau^{-} = 0.03$, $\Gamma^{-} = 91.09\%$, $H^{-} = 11.23$		0.38 [0.24, 0.52]	
Overall	0.28 [0.20, 0.37]		Test of $\theta_i = \theta_j$: Q(6) = 72.77, p = 0.00			
Heterogeneity: $\tau^2 = 0.02$, $I^2 = 86.91\%$, $H^2 = 7.64$				•		
Test of $\theta = \theta_j$: Q(13) = 95.57, p = 0.00			Overall		0.38 [0.27, 0.50]	
Test of group differences: $Q_b(2) = 2.31$, p = 0.31			Heterogeneity: $r^2 = 0.05$, $l^2 = 93.11\%$, $H^2 = 14.51$ Test of $\theta_i = \theta_i$: Q(14) = 173.39, p = 0.00			
0 .2 Random-effects REML model	.4 .6 .8		Test of group differences: $Q_b(2) = 2.72$, p = 0.26			
				0.5	1	

Random-effects REML model

Α				Effect Size	Weight	B		Effect Size	Weight
Study				with 95% CI	(%)	Study		with 95% CI	(%)
Νο ΝΜΑ						No NMA			
Dréno B et al. 2021		_		0.16 [0.01, 0.31] 6.78	Dréno B et al. 2021		0.16 [0.01, 0.31]	6.51
Duval L et al. 2015		_		0.20 [0.10, 0.30] 7.65	Duval L et al. 2015		0.20 [0.10, 0.30]	6.91
Fontana R et al. 2009				0.11 [0.01, 0.21] 7.65	Fontana R et al 2009		0.22 [0.08, 0.36]	6.60
Khammari A et al. 2009			_	0.42 [0.29, 0.55] 7.15	Khammari A et al. 2009		0.50 [0.37, 0.63]	6.68
Mackensen A et al. 2006				0.27 [0.14, 0.40] 7.15	Mackensen A et al. 2006		0.36 [0.22, 0.50]	6.60
Mitchell MS et al. 2002				0.10[0.01, 0.19	7.80	Mitchell MS et al. 2002		0.10 [0.01, 0.19]	6.98
Yee C et al. 2002/1				0.40 [0.18, 0.62] 5.49	Yee C et al. 2002/1		0.80 [0.62, 0.98]	6.22
Yee C et al. 2002/2				0.20 [0.01, 0.39	6.04	Yee C et al. 2002/2		0.80 [0.62, 0.98]	6.22
Heterogeneity: $\tau^2 = 0.01$, $I^2 = 71.83\%$, $H^2 = 3.55$	-			0.22 [0.14, 0.30]	Heterogeneity: $\tau^2 = 0.07$, $I^2 = 94.40\%$, $H^2 = 17.85$		0.39 [0.20, 0.58]	
Test of $\theta_i = \theta_j$: Q(7) = 24.36, p = 0.00						Test of $\theta_i = \theta_j$: Q(7) = 100.47, p = 0.00			
Yes NMA						Yes NMA			
Johnson LA et al. 2009/1				0.30 [0.20, 0.40	7.65	Chodon T et al. 2014		0.54 [0.40, 0.68]	6.60
Johnson LA et al. 2009/2		-		0.19[0.10, 0.28	7.80	Johnson LA et al. 2009/1		0.30 [0.20, 0.40]	6.91
Morgan RA et al. 2006				0.12 [0.04, 0.20] 7.94	Johnson LA et al. 2009/2		0.19 [0.10, 0.28]	6.98
Morgan 2013 RA et al. 2013				- 0.56 [0.40, 0.72] 6.60	Morgan RA et al. 2006		0.12 [0.04, 0.20]	7.04
Robbins PF et al. 2011				0.55 [0.44, 0.66	j 7.49	Morgan 2013 RA et al. 2013		0.56 [0.40, 0.72]	6.41
Robbins PF et al. 2015				0.45 [0.30, 0.60] 6.78	Robbins PF et al. 2011		0.55 [0.44, 0.66]	6.84
Heterogeneity: $\tau^2 = 0.03$, $I^2 = 91.77\%$, $H^2 = 12.15$				0.35 [0.20, 0.51]	Robbins PF et al. 2015		0.45 [0.30, 0.60]	6.51
Test of $\theta_i = \theta_j$: Q(5) = 61.32, p = 0.00						Heterogeneity: $\tau^2 = 0.03$, $I^2 = 91.09\%$, $H^2 = 11.23$		0.38 [0.24, 0.52]	
						Test of $\theta_i = \theta_j$: Q(6) = 72.77, p = 0.00			
Overall				0.28 [0.20, 0.37]				
Heterogeneity: $\tau^2 = 0.02$, $I^2 = 86.91\%$, $H^2 = 7.64$						Overall	-	0.38 [0.27, 0.50]	
Test of $\theta_i = \theta_j$: Q(13) = 95.57, p = 0.00						Heterogeneity: $\tau^2 = 0.05$, $I^2 = 93.11\%$, $H^2 = 14.51$			
Test of group differences: $Q_0(1) = 2.33$, p = 0.13						Test of $\theta_i = \theta_j$: Q(14) = 173.39, p = 0.00			
	0.2	.4	.6	.8		Test of group differences: $Q_b(1) = 0.00$, p = 0.96			
Random-effects REML model							0.5	1	
						Random-effects REML model			
						I			

A Study					Effect Size Weight with 95% CI (%)
1					
MAGE-A3		-			0.11 [0.01, 0.21] 7.65
MAGE-A3				_	— 0.56 [0.40, 0.72] 6.60
NYESO			-	-	0.55 [0.44, 0.66] 7.49
NYESO				 	0.45 [0.30, 0.60] 6.78
Heterogeneity: $\tau^2 = 0.04$, $I^2 = 91.49\%$, $H^2 = 11.75$					0.41 [0.20, 0.63]
Test of $\theta_i = \theta_j$: Q(3) = 44.53, p = 0.00					
Overall					0.41 [0.20, 0.63]
Heterogeneity: $\tau^2 = 0.04$, $I^2 = 91.49\%$, $H^2 = 11.75$ Test of $\theta_i = \theta_j$: Q(3) = 44.53, p = 0.00					
Test of group differences: $Q_0(0) = 0.00$, p = .					
	0	.2	.4	.6	.8
Random-effects REML model					
В					Effect Size Weight
Study					with 95% CI (%)
1		_			
MAGE-A3			_	_	0.22 [0.08, 0.36] 6.60
MAGE-A3				_	- 0.56 [0.40, 0.72] 6.41
NYESO			_		0.55 [0.44, 0.66] 6.84
NYESO		-			0.45[0.30, 0.60] 6.51
Heterogeneity: $\tau^2 = 0.02$, $I^2 = 80.97\%$, $H^2 = 5.25$					0.45 [0.29, 0.60]
Test of θ = θ _j : Q(3) = 15.98, p = 0.00					
Overall		-			0.45 [0.29, 0.60]
Heterogeneity: $\tau^2 = 0.02$, $I^2 = 80.97\%$, $H^2 = 5.25$					
Test of $\theta = \theta_{j}$: Q(3) = 15.98, p = 0.00					
Test of group differences: $Q_b(0) = 0.00$, p = .					
C)	.2	.4	.6	.8

Random-effects REML model





